Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Global Value Dossier

- PMLiVE

Medscape at ASH 2025: Landmark Value Through the Medscape AI Debut and Five Educational Symposia

For decades, Medscape has been the brand physicians trust. Now, Medscape is forging a new path into the future at ASH 2025 with the launch of Medscape AI — the...

Medscape Education

- PMLiVE

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

In 2022, nearly one million new patients were diagnosed with gastric cancer

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

- PMLiVE

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Around 9,000 people in the US currently live with SMA

- PMLiVE

Regeneron’s Libtayo receives EC approval for skin cancer

Phase 3 trial results showed the drug significantly improved disease-free survival

- PMLiVE

ESMO 2025 – ensuring innovation isn’t lost in translation

This year marks the congress’s 50th anniversary, with the theme: Many journeys. One global community

Printed version of 'The participation equation'

Behind the scenes: why we created ‘The participation equation’

Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research.

Cuttsy + Cuttsy

- PMLiVE

Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

Inizio

- PMLiVE

Sandoz launches first and only multiple sclerosis biosimilar in US

The treatment is FDA-approved to treat MS and Crohn’s disease

- PMLiVE

Tonix launches new oral fibromyalgia treatment

Tonmya is the first approved treatment for adults with fibromyalgia in over 15 years

R:SQD logo

Cuttsy+Cuttsy launches R:SQD – a new way to predict and improve trial success

Cuttsy+Cuttsy has launched R:SQD, an innovative recruitment and retention success scoring tool that helps clinical trial sponsors predict, measure, and improve participant engagement and trial outcomes.

Cuttsy + Cuttsy

- PMLiVE

Agility in medical affairs: responding to rapid market and regulatory shifts

By Maurice Leonard

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links